,

Sadiqua Shadbar1, Sathy Balu Iyer2, Jared Auclair3

  • 1Translational Medicine, Elektrofi Inc., Boston, MA 02210, USA; Department of Chemistry and Chemical Biology, College of Science, Northeastern University, Boston, MA 02115, USA.

概括

治疗性蛋白质免疫性是一个主要的挑战. 本综述详细介绍了影响免疫反应的因素以及评估和减轻更安全生物制药风险的策略.